Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics announced an investor webinar to discuss clinical updates from its CHM CDH17 and CHM CORE-NK programs. These programs are part of Chimeric’s efforts to advance its cell therapy portfolio, which shows promise in treating various cancers. The webinar aims to provide stakeholders with insights into the progress and future directions of these therapies, potentially impacting the company’s market positioning and stakeholder interests.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is an Australian clinical stage company specializing in cell therapy, particularly for cancer treatment. The company focuses on the discovery, development, and commercialization of innovative cell therapies, including autologous CAR T cell therapies and allogeneic NK cell therapies, with multiple programs in clinical stages.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.76M
See more data about CHM stock on TipRanks’ Stock Analysis page.